Schizophrenia News and Research

Latest Schizophrenia News and Research

Discovery of new receptor complex in brain - better understanding of how hallucinations occur

Mount Sinai researchers have identified a new receptor complex in the brain that responds to several types of antipsychotic drugs used to treat schizophrenia and also reacts to hallucinogenic drugs such as LSD.

27 Feb 2008

Vitamin D isn't just for bones anymore

Researchers at The Rockefeller University Hospital have begun a clinical study to explore a possible connection between vitamin D deficiency and insulin resistance.

21 Feb 2008

Siblings of schizophrenia patients display subtle shape abnormalities in brain

Subtle malformations in the brains of patients with schizophrenia also tend to occur in their healthy siblings, according to investigators at the Silvio Conte Center for the Neuroscience of Mental Disorders at Washington University School of Medicine in St. Louis. Shape abnormalities were found in the brain's thalamus.

20 Feb 2008

Australian neuroscientist tests Chantix

UQ pharmacy graduate Dr Selena Bartlett is starting clinical trials of a new drug that could potentially curb addictions such as smoking, drinking, gambling even depression.

20 Feb 2008

Music speeds up stroke recovery

A new study has found that listening to music can accelerate recovery from a stroke.

20 Feb 2008

Oxytocin hormone promotes bonding

Gazing into your lover's eyes isn't only romantic; it may also mimic early attachments that forever alter your brain and body.

11 Feb 2008

Study suggests Risperidone long-acting injection combined with standard treatment helped delay time to relapse in patients with bipolar disorder

Patients with frequently relapsing bipolar disorder had a significant delay in the time to an initial relapse when risperidone long-acting injection (RLAI) was combined with standard treatment, according to a new study. The study compared patients who received RLAI and standard treatment to those who received standard treatment combined with placebo.

4 Feb 2008

U.S. mental health survey of people with schizophrenia and providers

Mental Health America has released results of the first national online survey to examine overall healthcare in mental health settings from the perspective of both people with schizophrenia and psychiatrists.

31 Jan 2008

Mental and physical stimulation delays dementia in Huntington's disease

Scientists at Melbourne's Howard Florey Institute have discovered that mental and physical stimulation delays the onset of dementia in the fatal genetic disease, Huntington's disease.

25 Jan 2008

Genetic variant predicts antipsychotic response for schizophrenia patients by ethnicity

Schizophrenia is a developmental disorder with a large genetic component contributing to increased risk.

9 Jan 2008

Drug metformin and lifestyle changes can help treat weight gain induced by antipsychotic drugs

Lifestyle intervention and the drug metformin are both effective against antipsychotic-induced weight gain, and treatment is most effective when the two therapies are combined, according to a study in the January 9/16 issue of JAMA.

9 Jan 2008

Scientists can predict psychotic illness in up to 80 percent of high-risk youth

Youth who are going to develop psychosis can be identified before their illness becomes full-blown 35 percent of the time if they meet widely accepted criteria for risk, but that figure rises to 65 to 80 percent if they have certain combinations of risk factors, the largest study of its kind has shown.

8 Jan 2008

Placebo better than antipsychotic drugs for treating aggression in the intellectually disabled

Antipsychotic drugs which are commonly used to treat aggression in people who are intellectually disabled have been revealed to be ineffective.

6 Jan 2008

Scientists link depression to a biological mechanism that affects the olfactory glands

Can't smell the roses? Maybe you're depressed. Smell too much like a rose yourself? Maybe you've got the same problem.

4 Jan 2008

AstraZeneca submits sNDAs for SEROQUEL XR for bipolar symptoms

AstraZeneca has announced that the company has submitted two separate supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for once-daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder.

3 Jan 2008